FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979549672> ?p ?o ?g. }

• W2979549672 abstract "Abstract The German Study Group for High-Grade NHL (DSHNHL) investigated the efficacy of CHOP + Etoposide (Mega-CHOEP) at high doses for treatment of younger patients (pts) (<60y) with aggressive NHL and LDH > N. Autologous stem cells (ASC) were administered after the last 3 courses of therapy for hematopoietic rescue. At dose level (DL) 1 and 2 four courses of treatment were given: while doses of adriamycin (70 mg/m²), vincristine (2 mg), and prednisolon remained identical at all dose levels, the doses of Cyclophosphamide (C) and Etoposid (E) were set at 1500, 4500, 4500 6000 mg/m² (C), and 600, 600 (960), 600 (960), 1480 mg/m² (E) during courses 1, 2, 3 and 4 of therapy at DL1 (2). At DL 3 pts were randomized to receive either 4 (DL 3/4) or 6 courses of therapy (DL 3/6). While the cumulative doses of C and E were highest at DL 3 (C 19.5 g/m²; E 5.04 g/m²) as compared to DL 1 (C 16.5 g/m²; E 2.8 g/m²) or DL 2 (C 16.5 g/m²; E 4.0 g/m²) the administration of Mega-CHOEP with 6 courses of chemotherapy resulted in substantial prolongation of treatment (65 to 124 days) and thus loss of dose intensity (Table). From February 1997 to June 2001, 208 consecutive pts. were enrolled at DL 1–3, 31 of whom were excluded mostly due to incorrect histopathologie diagnosis. Therapy was given as per protocol in 81.8 % of pts. at DL 1 and 2, 90.2 % at DL 3/4 , and 69.2 % at DL 3/6, respectively, with treatment delays at DL 3/6 mostly due to extramedullary toxicity and, or poor performance status. Results were as follows: see table 1. Late events were very rare with 5 relapses beyond 2 years in the whole population. Dose escalation without higher dose intensity (DL1+2 vs DL3/4) did not improve results. Dose escalation with loss of dose intensity (DL1+2 and DL 3/4 vs DL3/6) resulted in loss of efficacy. Mega-CHOEP DL2 was selected for comparison with non-transplant therapy in an ongoing phase III trial. These data underscore the importance of early dose intensity for successful treatment of aggressive NHL with high risk features. Table 1 Therapy n IPI1/2/3(%) Duration of therapy (days) CRandCRu (%) TTTF2y (%) OS2y (%) DL 1+2 110 31/49/20 65 74 67 75 DL 3/4 41 20/46/34 80 68 53 70 DL 3/6 26 15/62/23 124 50 23 46" @default.
• W2979549672 created "2019-10-18" @default.
• W2979549672 creator A5002498295 @default.
• W2979549672 creator A5014979722 @default.
• W2979549672 creator A5023251571 @default.
• W2979549672 creator A5025105470 @default.
• W2979549672 creator A5029063148 @default.
• W2979549672 creator A5036867361 @default.
• W2979549672 creator A5039235274 @default.
• W2979549672 creator A5045752653 @default.
• W2979549672 creator A5067574718 @default.
• W2979549672 date "2004-11-16" @default.
• W2979549672 modified "2023-10-12" @default.
• W2979549672 title "Early Dose Intensity Is Critical in Patients with Aggressive Lymphoma: A Randomized study Comparing Identical Doses of Cyclophosphamide, Adriamycin, Vincristine, Etoposide, and Prednisolone given as 4 or 6 cycles followed by Repetitive Transplantation of Stem Cells (Mega-CHOEP)." @default.
• W2979549672 doi "https://doi.org/10.1182/blood.v104.11.9.9" @default.
• W2979549672 hasPublicationYear "2004" @default.
• W2979549672 type Work @default.
• W2979549672 sameAs 2979549672 @default.
• W2979549672 citedByCount "0" @default.
• W2979549672 crossrefType "journal-article" @default.
• W2979549672 hasAuthorship W2979549672A5002498295 @default.
• W2979549672 hasAuthorship W2979549672A5014979722 @default.
• W2979549672 hasAuthorship W2979549672A5023251571 @default.
• W2979549672 hasAuthorship W2979549672A5025105470 @default.
• W2979549672 hasAuthorship W2979549672A5029063148 @default.
• W2979549672 hasAuthorship W2979549672A5036867361 @default.
• W2979549672 hasAuthorship W2979549672A5039235274 @default.
• W2979549672 hasAuthorship W2979549672A5045752653 @default.
• W2979549672 hasAuthorship W2979549672A5067574718 @default.
• W2979549672 hasConcept C126322002 @default.
• W2979549672 hasConcept C141071460 @default.
• W2979549672 hasConcept C2776694085 @default.
• W2979549672 hasConcept C2776715498 @default.
• W2979549672 hasConcept C2776755627 @default.
• W2979549672 hasConcept C2778119113 @default.
• W2979549672 hasConcept C2779429289 @default.
• W2979549672 hasConcept C71924100 @default.
• W2979549672 hasConcept C90924648 @default.
• W2979549672 hasConceptScore W2979549672C126322002 @default.
• W2979549672 hasConceptScore W2979549672C141071460 @default.
• W2979549672 hasConceptScore W2979549672C2776694085 @default.
• W2979549672 hasConceptScore W2979549672C2776715498 @default.
• W2979549672 hasConceptScore W2979549672C2776755627 @default.
• W2979549672 hasConceptScore W2979549672C2778119113 @default.
• W2979549672 hasConceptScore W2979549672C2779429289 @default.
• W2979549672 hasConceptScore W2979549672C71924100 @default.
• W2979549672 hasConceptScore W2979549672C90924648 @default.
• W2979549672 hasLocation W29795496721 @default.
• W2979549672 hasOpenAccess W2979549672 @default.
• W2979549672 hasPrimaryLocation W29795496721 @default.
• W2979549672 hasRelatedWork W1976987645 @default.
• W2979549672 hasRelatedWork W1982518633 @default.
• W2979549672 hasRelatedWork W1983918413 @default.
• W2979549672 hasRelatedWork W2071615402 @default.
• W2979549672 hasRelatedWork W2093020189 @default.
• W2979549672 hasRelatedWork W2123774136 @default.
• W2979549672 hasRelatedWork W2183352065 @default.
• W2979549672 hasRelatedWork W2368204729 @default.
• W2979549672 hasRelatedWork W2416543910 @default.
• W2979549672 hasRelatedWork W3037061790 @default.
• W2979549672 isParatext "false" @default.
• W2979549672 isRetracted "false" @default.
• W2979549672 magId "2979549672" @default.
• W2979549672 workType "article" @default.